{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:37:14Z","timestamp":1769204234611,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bbrc.2022.07.045","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T03:01:29Z","timestamp":1657940489000},"page":"120-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway"],"prefix":"10.1016","volume":"623","author":[{"given":"Yi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangming","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.07.045_bib1","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.bbrc.2022.07.045_bib2","article-title":"Advances in management of bladder cancer","volume":"11","author":"Racioppi","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.bbrc.2022.07.045_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5152\/tud.2017.64624","article-title":"Alternative therapies in patients with non-muscle invasive bladder cancer","volume":"43","author":"Sanli","year":"2017","journal-title":"Turk J Urol"},{"key":"10.1016\/j.bbrc.2022.07.045_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12013-015-0632-6","article-title":"Recent advances in the diagnosis and management of bladder cancer","volume":"73","author":"Zhang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2022.07.045_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2022.07.045_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011102","article-title":"BET proteins as attractive targets for cancer therapeutics","volume":"22","author":"Sarnik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2022.07.045_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.acr.2016.04.001","article-title":"Small-molecule targeting of BET proteins in cancer","volume":"131","author":"French","year":"2016","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.07.045_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133210","article-title":"Epigenetic deregulation of apoptosis in cancers","volume":"13","author":"Ozyerli-Goknar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2022.07.045_bib9","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2022.07.045_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-020-01672-1","article-title":"Proteolysis targeting chimeras (PROTACs) in cancer therapy","volume":"39","author":"Ocana","year":"2020","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.07.045_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13046-016-0312-4","article-title":"Anti-tumor effects of Atractylenolide I on bladder cancer cells","volume":"35","author":"Yu","year":"2016","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.07.045_bib12","doi-asserted-by":"crossref","first-page":"37836","DOI":"10.18632\/oncotarget.6097","article-title":"JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis","volume":"6","author":"Heinicke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2022.07.045_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020162","article-title":"Bcl-2 family members and the mitochondrial import machineries: the roads to death","volume":"12","author":"Lalier","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2022.07.045_bib14","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.18632\/oncotarget.3551","article-title":"Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2022.07.045_bib15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2022.07.045_bib16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A\u00a0selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.bbrc.2022.07.045_bib17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0002-9440(10)64779-7","article-title":"Mechanisms of apoptosis","volume":"157","author":"Reed","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2022.07.045_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183716","article-title":"Apoptosis regulation at the mitochondria membrane level","volume":"1863","author":"Dadsena","year":"2021","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.bbrc.2022.07.045_bib19","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jid.2020.12.038","article-title":"A\u00a0combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma","volume":"141","author":"Emran","year":"2021","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.bbrc.2022.07.045_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061292","article-title":"Targeting BCL-2 in cancer: advances, challenges, and perspectives","volume":"13","author":"Hafezi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2022.07.045_bib21","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","article-title":"Discovery of a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition","volume":"64","author":"Pal","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2022.07.045_bib22","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","article-title":"BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members","volume":"15","author":"Hogg","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2022.07.045_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12672-022-00470-9","article-title":"Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells","volume":"13","author":"Abdul Rahman","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1016\/j.bbrc.2022.07.045_bib24","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","article-title":"Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition","volume":"37","author":"Weeden","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2022.07.045_bib25","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/leu.2016.52","article-title":"BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells","volume":"30","author":"Xu","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2022.07.045_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.celrep.2013.12.001","article-title":"BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction","volume":"6","author":"Patel","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2022.07.045_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canlet.2018.07.033","article-title":"Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy","volume":"435","author":"Qian","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2022.07.045_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22010142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22010142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:20:51Z","timestamp":1757766051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22010142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":28,"alternative-id":["S0006291X22010142"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.07.045","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}